Protocol Ledger

NCT06789913 · Phase II · RECRUITING

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)

Interventional Phase II clinical trial protocol NCT06789913 sponsored by Relay Therapeutics in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-06-13 Enrollment: 277 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06789913
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)277 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06789913
Protocol FieldVerified Registry Value
NCT IdentifierNCT06789913
Consolidated Lead SponsorRelay Therapeutics
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment277 participants (ESTIMATED)
Registered Start Date2025-06-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI